MicroRNA-105 is Involved in TNF-α-related Tumor Microenvironment Enhanced Colorectal Cancer Progression
Overview
General Medicine
Authors
Affiliations
TNF-α is a central proinflammatory cytokine contributing to malignant tumor progression in tumor microenvironment. In this study, we found the upregulation of miR-105 in colorectal cancer was associated with aggressive phenotype, and the enhanced expression of miR-105 was required for TNF-α-induced epithelial-mesenchymal transition (EMT). The expression of miR-105 was remarkably stimulated by TNF-α in a time-dependent manner using real-time qPCR analysis. Inhibition of miR-105 remarkably weakened the aggressive effects of TNF-α through preventing the activation of NF-κB signaling and the initiation of EMT. Furthermore, miR-105 was demonstrated directly targeted on the 3'-UTRs of RAP2C, a Rap2 subfamily of small GTP-binding protein. Consistently, suppression of RAP2C stimulated the role of miR-105, which dramatically promoted the invasion and metastasis of CRC cells. Thalidomide, a TNF-α and NF-κB inhibitor, significantly weakened the metastasis and homing capacity of miR-105-overexpressed CRC cells in nude mice. Our investigation initiatively illustrated the modulatory role of miR-105 in TNF-α-induced EMT and further CRC metastasis. We also offer a better understanding of TNFα-induced metastasis and suggest an effective therapeutic strategy against CRC metastasis.
Genetic variants in mitochondrial sirtuins associated with brain tumor risk: a case-control study.
Fazal Ul Haq M, Hussain M, Haris M, Kayani M, Mahjabeen I Future Oncol. 2024; 20(40):3421-3432.
PMID: 39560005 PMC: 11776854. DOI: 10.1080/14796694.2024.2429948.
Tariq L, Arafah A, Sehar N, Ali A, Khan A, Rasool I Med Oncol. 2023; 40(10):282.
PMID: 37639075 DOI: 10.1007/s12032-023-02099-2.
Silva K, Franca D, de Queiroz A, Fagundes-Triches D, de Marchi P, Morais T Int J Mol Sci. 2023; 24(15).
PMID: 37569777 PMC: 10419558. DOI: 10.3390/ijms241512400.
Zmarzly N, Januszyk S, Mieszczanski P, Czarniecka J, Bednarska-Czerwinska A, Boron D J Cancer Res Clin Oncol. 2023; 149(12):9679-9689.
PMID: 37233761 PMC: 10423110. DOI: 10.1007/s00432-023-04863-3.
Borowczak J, Szczerbowski K, Maniewski M, Kowalewski A, Janiczek-Polewska M, Szylberg A Biomedicines. 2022; 10(7).
PMID: 35884974 PMC: 9312930. DOI: 10.3390/biomedicines10071670.